A novel therapy for lymphoma & atherosclerosis - identification of commercialisation approaches
Lead Research Organisation:
Aston University
Department Name: Sch of Life and Health Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
| Description | The findings from this award has helped to guide new commercialisation approaches, for different indications (when combined with the outcome of other BBSRC grants). Through the use of NXNW-ICURE funding (two round) additional funding applications are in progress and a University Spin out is in process |
| First Year Of Impact | 2022 |
| Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Description | A novel therapy for lymphoma & atherosclerosis - identification of commercialisation approaches |
| Amount | £10,717 (GBP) |
| Funding ID | BB/S000011/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 11/2018 |
| Description | Active Extracellular Vesicles - defining a novel, extracellular metabolic compartment and its role in the control of inflammation. |
| Amount | £777,973 (GBP) |
| Funding ID | BB/S00324X/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2021 |